Sundar PichaiSundar Pichai earned $164M in 2023

Marino Garcia is the CEO of Dianthus Therapeutics, appointed in September 2023, following a significant transition in company leadership. He has a solid foundation in business with an M.B.A from Ivey Business School and a Bachelor of Commerce from Concordia...

Quick Links
D

Marino Garcia

CEO of Dianthus Therapeutics

Education

M.B.A. from the Ivey Business School at Western University and Bachelor of Commerce from Concordia University

Field of Expertise

Business & Management - Business Development

Sector of Economy

Healthcare

Born

January 1, 1966 - 59 years ago

CEO of Dianthus Therapeutics for

1 year 7 months (Sep 2023 - Present)

Previous Experience

Senior Vice President, Corporate and Business Development at Zealand Pharma A/S

Rivals

Competitors/colleagues of Marino Garcia

Holdings

See how much did Marino Garcia make over time.

Marino Garcia holds a stake in Dianthus Therapeutics, where he began as CEO in September 2023. Before this, he was involved in various leadership roles in the biopharmaceutical sector, leading to a wealth of experience. His holdings reflect his commitment...

Insider Trading

See recent insider trades of Marino Garcia.

No insider trades found for this CEO.

Compensation History

See how much did Marino Garcia make over time.

In 2023, Marino Garcia's total compensation as CEO of Dianthus Therapeutics amounted to $496,022. This includes a base salary of $174,863 and a performance-based bonus of $321,159, which demonstrates his focus on achieving company milestones in drug development. His compensation structure is designed to align closely with the company’s performance, aiming to motivate leadership to meet critical business objectives. Garcia's pay reflects his accountability for the future of Dianthus, especially following the company's recent merger and subsequent changes in strategy. The company adopts a philosophy of tying executive pay directly to performance metrics, which in Garcia's case means achieving success in clinical trials and pipeline development, two key areas of focus for his leadership team.

Year

2023

Total Compensation

$496.02K

Salary

$174.86K

Board Justification

The compensation philosophy focuses on aligning executive compensation with company performance, peer benchmarking, and retention strategies, aiming to motivate executives to achieve short- and long-term results in the best interests of stockholders.

Bonus

$321.16K

Board Justification

The bonus is based on the annual cash incentive payouts earned for performance in 2023, which are expected to be paid in February 2024. The annual incentive program was based on achievement of corporate performance goals related to clinical trial readiness and pipeline development, with payouts approved at 115% of target.

Other

$0.00

Board Justification

No other compensation was reported for 2023.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock was reported as vested in 2023.

Performance Metrics

The performance metrics for determining compensation in 2023 included execution towards organizational readiness for clinical trials and pipeline development.

Other Dianthus Therapeutics CEOs

Here are other CEOs of Dianthus Therapeutics